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Abstract: Diseases of the kidney are difficult to diagnose and treat. This review summarises
the definition, cause, epidemiology and treatment of some of these diseases including chronic
kidney disease, diabetic nephropathy, acute kidney injury, kidney cancer, kidney transplantation and
polycystic kidney diseases. Numerous studies have adopted a metabolomics approach to uncover
new small molecule biomarkers of kidney diseases to improve specificity and sensitivity of diagnosis
and to uncover biochemical mechanisms that may elucidate the cause and progression of these
diseases. This work includes a description of mass spectrometry-based metabolomics approaches,
including some of the currently available tools, and emphasises findings from metabolomics studies
of kidney diseases. We have included a varied selection of studies (disease, model, sample number,
analytical platform) and focused on metabolites which were commonly reported as discriminating
features between kidney disease and a control. These metabolites are likely to be robust indicators of
kidney disease processes, and therefore potential biomarkers, warranting further investigation.
Keywords: acute kidney injury; chronic kidney disease; diabetic nephropathy; kidney cancer;
kidney disease; kidney transplantation; polycystic kidney disease; biomarker; chromatography;
mass spectrometry; metabolomics
1. Introduction
The roles of the kidney include excretion, hormone production, regulation of blood pressure,
and ionic, osmotic and pH balance [1,2], all of which make the kidney essential for physiological
homeostasis [3,4]. Due to its many roles, diseases of the kidney often have systemic consequences
making diagnosis and treatment extremely difficult and expensive. Kidney Health Australia,
for example, estimates that the Australian government will be spending 7–8 billion dollars on the
treatment of end-stage renal disease by 2020 [5]. Here we provide a description of some common
nephropathies and their current status in terms of definition/diagnosis, aetiology, epidemiology and
therapy/treatment. Also, the general workflow and available tools for conducting metabolomics
experiments is provided. The purpose of this review is to assess a range of metabolomics studies
since this approach can potentially determine metabolites of interest in kidney diseases, aiding the
development of new diagnostic approaches and therapeutic targets for treatment. After providing
a summary of kidney diseases and metabolomics, we examined a diverse selection of metabolomics
studies of kidney diseases with the aim of highlighting metabolites which are consistently reported
regardless of the disease model, study population size, sample type and/or analytical platforms used.
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Given that some overlap exists in the aetiology of some kidney diseases, these metabolites provide
some insight into the biochemical processes linking different kidney diseases.
2. Kidney Disease
There are many kidney diseases that are difficult to diagnose and treat despite a long history of
studying the kidney and associated diseases. In his review, ‘Kidney’, Smith [6] cited literature from
1935, however it is known that the diagnoses of kidney disease dates back to at least the 1500s [7,8].
Treatments for chronic kidney disease are often invasive and expensive, and there are no known cures
for chronic kidney diseases [5] or injuries [9]. Therefore, current research aims to develop targeted and
effective diagnosis and treatment. We have included here a description of acute kidney injury (AKI)
and chronic kidney disease (CKD) as they are often referred to as stand-alone conditions, and kidney
transplantation, even though it is a therapy. In fact, AKI can be a result of, for example, reperfusion after
transplantation, and conditions such as polyscystic kidney diseases (PKD), and diabetic nephropathy
may result in CKD and the need for transplantation. Furthermore, AKI may develop in patients with
CKD and vice versa [10]. These relationships are depicted in Figure 1.
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Figure 1. The overlapping relationships of the described kidney diseases. Chronic kidney disease
and sub-entities: Polycystic kidney disease, diabetic nephropathy, kidney cancer and membranous
nephropathy may progress to end-stage renal disease requiring transplantation. Reperfusion after
transplantation may result in acute kidney injury. Acute kidney injury may also result from sub-entities
of CKD.
2.1. Chronic Kidney Disease
CKD, the loss of kidney function over time (eGFR < 60 mL/min/1.73 m2 for three months or
more [11]), affects 8–10% of individuals in Western Countries [12]. CKD has been classified into
five stages according to glomerular filtration rate (GFR) or estimated GFR (eGFR; mL/min/1.73 m2).
Creatinine-based estimations of GFR are most commonly used, however estimations based on cystatin
C may also be used [13]. Table 1 lists the five stages of CKD [11] and further includes the classification
of Stage 3 as 3a (45–59 mL/min/1.73 m2) or 3b (30–44 mL/min/1.73 m2). With no available cure
for CKD, therapies centre on managing symptoms with renal replacement therapies such as dialysis
and/or transplantation.
Metabolites 2019, 9, 34 3 of 22
Table 1. Stages of chronic kidney disease as defined by glomerular filtration rate (GFR) or estimated
glomerular filtration rate (eGFR).
Stage GFR or eGFR (mL/min/1.73 m2)
1 ≥ 90
2 60–89
3 30–59
3a 45–59
3b 30–44
4 15–29
5 <15
2.2. Diabetic Nephropathy
Diabetic nephropathy is the leading cause of chronic kidney disease, affecting approximately
30 to 40% of type 1 diabetes mellitus patients and 25 to 40% of type 2 diabetes patients [14–17].
Diabetic nephropathy is characterised by the combination of insulin- or non-insulin dependent diabetes
with persistent microalbuminuria [17]. There is a genetic predisposition to diabetic nephropathy,
however the most important risk factor is hyperglycaemia [17] and therefore management of diabetic
nephropathy includes glycaemic control and pancreas transplantation to treat diabetes. It has been
suggested that oxidative stress drives diabetic nephropathy through mitochondrial production of
reactive oxygen species in response to hyperglycaemia [18]. Other factors contributing to progression
include hyperlipidaemia, hypertension and proteinuria [17].
2.3. Acute Kidney Injury (AKI)
AKI is characterised by rapid loss of renal function [19] and may occur as a result of ischaemic
or toxic damage to the kidney, both of which can also be caused by inflammation. AKI is diagnosed
by increased serum creatinine and blood urea nitrogen (BUN; serum or plasma urea), estimation of
glomerular filtration rate and urine output [19]. There are five stages of AKI for which patients
are diagnosed based on the results: Risk, injury, failure, loss and end-stage renal disease (ESRD;
RIFLE) [19,20] with loss and ESRD being outcomes of AKI rather than stages [9]. AKI is typically
diagnosed after loss of renal function; therefore, risk factors have been identified and a number
of early biomarkers which precede kidney damage have been proposed. Patient risk factors
include sepsis, major surgery, bleeding and blood volume loss, and those with increased serum
neutrophil gelatinase-associated lipocalin (NGAL), cystatin C and/or increased urinary NGAL,
interleukin 18 (IL-18), kidney injury molecule 1 (KIM-1), glutathione S-transferase (GST) and liver-type
fatty acid-binding protein (LFABP). All of these factors have been linked to kidney injury or
disease [9,19,21–26] and have been recommended by Bellomo [19] as early biomarkers of AKI.
2.4. Kidney Cancer
The incidence of renal cell carcinoma (RCC), the most common kidney cancer, is increasing [27].
The known subtypes of RCC are, in order of prevalence, clear cell (ccRCC), papillary (pRCC),
chromophobe and collecting duct tumours [28]. In their review, Rini, Campbell and Escudier [29]
estimated that the incidence of RCC is 209,000 new cases per year worldwide, with 102,000 deaths per
year despite recent advances in drug therapies and surgical interventions. As well as genetic factors,
the risk factors for developing RCC are smoking, obesity and hypertension [30]. Patients may present
with local or systemic symptoms [29], however detection of RCC is usually early though incidental
due to the recent widespread use of abdominal imaging. Stages 1 and 2 RCC outlined by Cohen and
McGovern [30] are tumours less than (stage 1) or greater than (stage 2) 7 cm and limited only to the
kidney. The 5-year survival for stages 1 and 2 is 95% and 88% respectively. Five-year survival declines
to 59% and 20% for stages 3 and 4 respectively once tumours are beyond the kidney and lymph nodes
are involved [30].
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2.5. Kidney Transplantation
Kidney transplantation is a long-term treatment for chronic kidney diseases, however there
are known risk factors associated with transplant rejection including acute rejection episodes, age,
delayed graft function, diabetes, ethnicity and human leukocyte antigen (HLA) mismatching [31],
with HLA matching the most robust predictor for transplant success [32]. Lee et al. [33] found
that 100% of patients in their study developed human leukocyte antigen (HLA) antibodies prior to
chronic rejection, however HLA antibodies also developed in patients without chronic rejection (27%).
Detailed criteria for assessing histologic data from graft biopsy have been determined [34], as well
as less invasive assessments. For example, in their 11-year study of over 100,000 kidney transplants,
Hariharan et al. [31] found that serum creatinine (SCr) at 6 and 12 months post graft and delta SCr in
the first year post graft would predict survival long-term.
2.6. Polycystic Kidney Diseases
PKDs are characterised by cyst formation, tubular defects and kidney enlargement and resultant
dysfunction. There are at least two stages in the formation of cysts in PKD [35], the development and
encapsulation of the cysts, and cyst growth [35]. It has been postulated that primary cilia are involved
in PKD cystogenesis due to their role in the transport of cystoproteins (i.e., fibrocystin/polyductin) [36].
Renal cyst formation presents as a pathologic feature in Bardet-Beidl and Meckel-Gruber syndromes and
the nephronophthisis (NPHP) group of ciliopathies [37], to which over 20 genes have been linked [38].
The most common presentation however is autosomal dominant polycystic kidney disease (ADPKD).
ADPKD has an incidence of approximately 1:400–1000 worldwide [39,40], making up 10% of
adult patients with chronic renal failure requiring dialysis and/or transplantation [40]. ADPKD results
in ESRD in 50% of patients by the age of 60 years [39,40] with hypertension, vascular aneurisms,
cardiac valve defects and colonic diverticulae all associated with ADPKD due to the systemic nature of
the disease [40]. ADPKD is caused by mutations in the Pkd1 (16p13.3) or Pkd2 (4q21–23) genes [41,42],
however, there is evidence to suggest that a third locus exists [39,43]. Ariza et al. (1997) identified
a Spanish family which presented with a mild form of ADPKD and showed negative linkage to the
Pkd1 or Pkd2 loci. The phenotypes of the disease have been linked to the genotype, with the Pkd2 form
resulting in a much milder form and presenting later in life than the Pkd1 form [39]. Although this
pattern exists, variation within genotypes has been documented [40].
Autosomal recessive PKD (ARPKD) is less common, with an incidence of approximately
1 in 10,000–40,000, commonly evident in utero, with diagnosis by ultrasound at approximately
20 weeks [44–47] or at birth. Various clinical presentations have been observed in ARPKD [44],
with the disease presenting as early as prenatally up to adulthood [41]. Arbeiter et al. (2008)
postulated that, as with the ADPKD phenotypes, the severity of the ARPKD phenotype could not be
explained by the genetic mutations [39] and more likely depends on other genes, epigenetic factors,
environmental influences and potential modifier genes which have been identified in the described
mouse models of PKD [48].
ARPKD is caused by mutations in the Pkhd1 gene on chromosome 6p12 [46] and is characterised
by oligohydramnion, enlarged kidneys and lung hypoplasia [46]. The disease is also commonly
characterised by fusiform dilation of the collecting ducts and distal tubules, as well as dysgenesis
of the hepatic portal triad [46]. In up to 75% of severe cases, death is often caused by respiratory
insufficiency and displacement of the diaphragm soon after birth. Neonates who do not exhibit
pulmonary hyperplasia have a 50–80% survival rate. Of patients who survive the neonatal period,
approximately 30% progress to end-stage kidney disease, commonly with hypertension and multiple
organ failure [46].
In the past, depending upon the expressed phenotype of the disease, the management of ARPKD
has been documented as aggressive [46,49]. Unilateral or bilateral nephrectomy has been described in
four severe cases since 1993 [46,49]. It is of course likely that there are undocumented cases. In their
case report, Arbeiter et al. (2008) described the treatment steps taken to alleviate the symptoms
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of ARPKD in a newborn female. ARPKD diagnosis was achieved using ultrasound and chest
x-ray, and later confirmed histologically and genetically. Mechanical ventilation, administration
of furosemide, hydrochlorothiazide, amlodipine, other diuretics and ultimately unilateral nephrectomy
were included in the treatment strategy, however the patient died 27 days after birth. For presentations
of ARPKD which are less severe, such as slow progression and presentation in later childhood or
adulthood, treatment has still been described as invasive, i.e., renal replacement therapy.
There is currently no cure available for PKD [36], however with recent approaches in
understanding the molecular pathogenesis and cystogenesis of the disease, such as targeting mTOR
activity [50], EGFR axis [46], and cAMP-activated B-Raf/ERK [51,52] and (IRS) PI3K/Akt [53] signalling
pathways, new therapies and management strategies are emerging and advancing into clinical
trials [36]. In recent preclinical models of PKD, Bukanov et al. [54] and Natoli et al. [55] have shown
that inhibition of dysregulated cell cycle and apoptosis with the CDK inhibitor, roscovitine, leads to
arrest of PKD.
3. Metabolomics
Downstream of genomics, transcriptomics and proteomics, metabolomics is the comprehensive
study of metabolites in the cell, tissue and/or biofluids, collectively known as the metabolome, of an
organism [56]. A metabolite is typically defined as a small molecule intermediate or product of
metabolism of molecular weight less than 1500 Daltons [57]. Metabolism is a close representation of the
phenotype [58], and with its capacity to represent the function of an organism as a result of a disease
or environmental stress at a particular time [59], it is not surprising that metabolomic approaches have
been gaining popularity.
A comprehensive database of the human metabolome has been compiled (The Human
Metabolome Database; HMDB; [60–63]) including over 100,000 known, expected and predicted
metabolites with compound origin, biofluid/tissue location, spectra and reference ranges if available.
The HMDB classifies metabolites by super class, class and sub class with sub class including well
known metabolites classes such as amino acids, carbohydrates, and fatty acids.
Metabolomics aims to detect both endogenous and exogenous metabolites including small
molecules taken up from food, medicines and the environment. There are two key approaches in
metabolomic experiments, termed targeted and untargeted, although there are many terminologies for
these approaches in the literature [64,65]. Targeted experiments are conducted when pre-defined
metabolites are of interest and their concentrations (relative, semi-quantitative or absolute) are
subsequently measured. Untargeted approaches are conducted when there is no prior knowledge
of the metabolites being measured and the concentrations (relative or semi-quantitative) of as many
metabolites as possible are determined. In the context of this review, both approaches may determine
metabolites which differentiate between, for example, individuals with kidney disease and healthy
individuals, though novel markers are more likely to be uncovered using an untargeted approach.
The analytical platforms with which metabolomic experiments are conducted are predominantly
nuclear magnetic resonance (NMR) spectroscopy and chromatography-mass spectrometry (MS),
however other techniques have been described [66] and complementary platforms are desirable
for greater metabolome coverage [67]. NMR spectroscopy provides a quantitative, robust platform
that requires larger volumes of sample, but minimal sample preparation. MS provides sensitivity
which ultimately gives a greater metabolome coverage within a single injection, but is less robust and
requires detailed sample preparation, though smaller sample volumes may be used. We focus on mass
spectrometry approaches in further detail in the following sections however findings from NMR-based
studies are included in the final section.
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Table 2. Selection of metabolomic studies of kidney disease. n = minimum number of samples in a study group reported for any sample type.
Kidney Disease Reference Model n Sample Type Analytical Platform
Acute kidney injury Sun, 2012 [123] Human 17 Serum LC-MS
Chronic kidney disease
Shah, 2013 [124] Human 10 Plasma GC-MS, LC-MS
Zhao, 2013 [122] Rat 8 Kidney tissue LC-MS
Boelaert, 2014 [121] Human 20 Serum GC-MS, LC-MS
Luck, 2016 [125] Human 110 Urine NMR
Rhee, 2016 [126] Human 200 Plasma LC-MS
Sekula, 2016 [127] Human 991 Serum GC-MS, LC-MS
Kobayashi, 2015 [128] Human 69 Plasma LC-MS
Zhao, 2013 [129] Rat 12 Kidney tissue LC-MS
Atzori, 2011 [130] Human 13 Urine NMR
Nkuipou-Kenfack, 2014 [131] Human 10 Plasma, urine LC-MS
Mutsaers, 2013 [132] Human ≥4 Plasma NMR
Zhang, 2015 [133] Rat 8 Urine LC-MS
Qi, 2012 [134] Human 20 Serum NMR
Zhao, 2013 [135] Rat 8 Serum LC-MS
Goek, 2013 [136] Human 87 Serum LC-MS, FIA-MS
Diabetic nephropathy
Van der Kloet, 2012 [15] Human 26 Urine GC-MS, LC-MS
Stec, 2015 [137] Mouse 11 Urine NMR
Sharma, 2013 [138] Human 12 Plasma, urine GC-MS
Zhao, 2012 [139] Rat 12 Kidney tissue GC-MS, LC-MS
You, 2015 [140] Mouse 11 Urine GC-MS
Makinen, 2012 [141] Human 86 Serum NMR
Makinen, 2008 [142] Human 137 Serum NMR
Makinen, 2013 [143] Human 63 Serum NMR
Barrios, 2018 [144] Human 926 Serum NMR
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Table 2. Cont.
Kidney Disease Reference Model n Sample Type Analytical Platform
Kidney cancer Kind, 2007 [145] Human 6 Urine GC-MS, LC-MS
Kim, 2011 [146] Human 11 Urine LC-MS
Kidney transplantation
Serkova, 2005 [147] Rat 6 Kidney tissue, wholeblood NMR
Stenlund, 2009 [148] Human 19 Urine NMR
Suhre, 2016 [149] Human 241 Urine, kidney tissue GC-MS, LC-MS
Membranous
nephropathy Gao, 2012 [150] Human 14 Serum, urine GC-MS
Polycystic kidney disease
Taylor, 2010 [151] Mouse 9 Urine GC-MS
Toyohara, 2011 [152] Mouse 5 Plasma CE-MS
Abbiss, 2012 [120] Rat 6 Urine GC-MS
Gronwald, 2011 [153] Human 10 Urine NMR
Hwang, 2015 [154] Mouse, human 2 Cells, plasma, tissue,urine GC-MS, LC-MS
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Table 3. Metabolites which have been reported as important for two or more kidney diseases from the list of studies in Table 2. Darker colour indicates metabolite
reported in greater number of kidney diseases. CKD: Chronic kidney disease; DN: Diabetic nephropathy; PKD: Polycystic kidney disease, AKI: Acute kidney injury; T:
Kidney transplantation; MN: Membranous nephropathy; KC: Kidney cancer. *sub class not available, #class provided, ¥super class provided, §not classified.
Metabolites Sub Class
Kidney Disease
CKD DN PKD AKI T MN KC
allantoin imidazoles [122,129] [139] [120,152] [147]
quinolinic acid pyridinecarboxylic acids &derivatives [121] [149] [150] [146]
2-hydroxyglutarate short-chain hydroxy acids &derivatives [15,139] [154] [150]
2-oxoglutaric acid gamma-keto acids & derivatives [137] [120,152] [146]
aconitic acid tricarboxylic acids & derivatives [138] [152] [150]
ADMA amino acids, peptides & analogues [131,136] [152] [123]
carnitine quaternary ammonium salts [124,125] [15] [152]
citrate tricarboxylic acids & derivatives [124,125] [138,139] [152–154]
creatinine amino acids, peptides & analogues [121,125,127,132,133,135] [152] [123]
hippuric acid benzoic acids & derivatives [122,128,132] [15,137,139] [120,152]
kynurenic acid quinoline carboxylic acids [121] [15] [149]
LysoPC (16:1) Glycerophosphocholines [135] [139] [123]
malic acid beta hydroxy acids & derivatives [124] [139] [154]
methionine amino acids, peptides & analogues [121,126] [139] [123]
myo-inositol alcohols & polyols [127,132,134] [139] [152] [149]
threonic acid carbohydrates & conjugates [124] [139] [150]
trimethylamine oxide aminoxides [132] [152] [149]
tryptophan indolyl carboxylic acids &derivatives
[121,133,
135] [15] [123]
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uric acid purines & purine derivatives [121,122,126] [139] [120]
valine amino acids, peptides & analogues [130,135] [144] [149]
2-furoylglycine amino acids, peptides & analogues [121] [146]
3-indoxyl sulfate arylsulfates [137] [152]
3-methylhistidine amino acids, peptides & analogues [132,133] [152]
4-pyridoxic acid pyridinecarboxylic acids &derivatives [121] [139]
4-hydroxymandelate 1-hydroxy-2-unsubstitutedbenzenoids [126] [149]
acetylcarnitine fatty acid esters [152] [123]
alanine amino acids, peptides & analogues [121,134] [139,144]
arachidonic acid fatty acids & conjugates [122,124,129] [139]
arginine amino acids, peptides & analogues [122,126] [123]
citrulline amino acids, peptides & analogues [124,131] [152]
cytosine pyrimidines & pyrimidinederivatives [126] [150]
fructose carbohydrates & conjugates [139] [146]
fumaric acid dicarboxylic acids & derivatives [140] [154]
gentisate benzoic acids & derivatives [149] [146]
glucose carbohydrates & conjugates [134] [139]
glutamic acid amino acids, peptides & analogues [15] [154]
glutamine amino acids, peptides & analogues [121,130] [154]
glycine amino acids, peptides & analogues [125,130,134] [152]
homocysteine amino acids, peptides & analogues [133] [123]
hypoxanthine purines & purine derivatives [122] [153]
indole acetic acid indolyl carboxylic acids &derivatives [121] [15]
indoxyl sulfate arylsulfates [121,122,128,129] [139]
lactic acid alpha hydroxy acids & derivatives [134] [139]
leucine amino acids, peptides & analogues [131] [149]
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Table 3. Cont.
lysine amino acids, peptides & analogues [121] [139]
Lyso PC (16:0) Glycerophosphocholines [135] [123]
Lyso PC (18:0) Glycerophosphocholines [135] [123]
Lyso PC (18:2) Glycerophosphocholines [135] [123]
Lyso PC (20:4) *§ [135] [139]
N,N-dimethylglycine amino acids, peptides & analogues [132] [152]
ornithine amino acids, peptides & analogues [124] [139]
pantothenic acid polyols [121] [152]
phenylacetylglycine amino acids, peptides & analogues [129] [137]
phenylalanine amino acids, peptides & analogues [126,133] [123]
phosphate non-metal phosphates [124] [139]
pipecolate amino acids, peptides & analogues [152] [149]
proline amino acids, peptides & analogues [121,131] [149]
pseudouridine nucleoside & nucleotideanalogues*#
[121,127,
132] [15]
pyroglutamic acid amino acids, peptides & analogues [139] [123]
taurine organosulfonic acids & derivatives [134] [139]
tetracosahexaenoate fatty acids & conjugates [122] [139]
threonine amino acids, peptides & analogues [126] [139]
trigonelline alkaloids & derivatives*¥ [125,132] [153]
urea ureas [121] [139]
xanthosine purine nucleosides*# [121] [149]
xylitol carbohydrates & conjugates [149] [150]
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3.1. Sample Collection, Preparation, Storage and Handling
The selection of an appropriate sample to study and the way in which it is collected, prepared,
stored and handled will, in combination with extraction, analytical platform, data analysis and
metabolite identification, be key to the interpretation of results. A review by Walsh et al. [68] identified
the challenges in metabolomic research regarding each stage of a metabolomic experiment, but with
a particular focus on sample collection, preparation storage and handling. [69] The impacts of such
pre-analytical procedures on plasma and serum metabolomes have recently been reviewed in detail by
Yin, Lehmann and Xu [70]. As an example, an endogenous metabolite was found in varying levels as
a contaminant in different plasma and serum vacutainer tubes [69] which highlights the importance
of keeping protocols consistent. There are still no agreed methods for the collection, preparation,
storage and handling of samples for a metabolomic experiment [71,72], however the Metabolomics
Standards Initiative (MSI) [73] have recommended reporting criteria for mammalian/in vivo biological
samples [74].
In addition to experimental samples for MS-based untargeted metabolomic experiments, it is
now widely accepted that pooled quality control samples providing technical replication throughout
an analytical sequence and batches of sequences should be used [75]. Similarly, reference samples
or test mixtures have been proposed to assess analytical performance [76,77]. For the subtraction of
artefacts introduced through sample collection, preparation, storage, handling, extraction and analysis,
‘method’ or ‘blank’ samples should also be processed throughout these stages.
3.2. Metabolite Extraction
The physicochemical properties of metabolites vary greatly and therefore cannot be extracted
with a single solvent, nor analysed on a single analytical platform [78]. Many studies report
adaptations of the Bligh and Dyer lipid extraction method [79] to utilise both polar and non-polar
fractions. Metabolite extraction methods include steps for protein precipitation, metabolite extraction
(usually a single step for both) and filtration or other form of sample clean-up such as solid
phase extraction (SPE) [65]. Commonly reported solvents for the precipitation of protein and
metabolite extraction are acetonitrile, methanol and water, though acidification and heating have also
been described.
3.3. Chromatographic Separation
Chromatographic separation of analytes prior to detection reduces the complexity of spectra for
sample matrices by reducing interference from neighbouring peaks and aids in the identification of
metabolites by providing retention time (and/or index) information for a compound. It is not always
possible however to resolve all peaks, particularly in untargeted analyses. Chromatography coupled
to MS has been used extensively in metabolomic research [80], the most common platforms being gas
chromatography (GC) and liquid chromatography (LC).
3.3.1. Gas Chromatography
Gas chromatography has been widely used in metabolomics-based research [81] and has
demonstrated good metabolome coverage (i.e., detection of a variety of metabolite physicochemical
properties), as well as detecting unique compounds in the human serum and urine metabolomes [82,83].
Gas chromatography is ideal for low molecular weight volatile compounds and in metabolomic
experiments, provides superior chromatographic resolution and retention time reproducibility when
compared to liquid chromatography. To give greater metabolome coverage, however, some metabolites
must first be derivatised. Derivatization reduces polarity, increases thermal stability and improves
resolution and peak shape/intensity [84,85]. Derivatisation can be cumbersome and artefacts and
multiple derivatisation products can be observed, however there has been good uniformity in GC-MS
based methods allowing the curation of extensive databases for the identification of metabolites
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analysed by GC-MS, such as the National Institute of Standards and Technology (NIST) Mass
Spectral Database. Examples of public libraries for the identification of GC-MS spectra include
Golm Metabolome Database [86] and FiehnLib mass spectral library [87].
3.3.2. Liquid Chromatography
Liquid chromatography approaches can capture a wider range of metabolite physicochemical
properties than GC-MS and have generally yielded more sensitive acquisitions and hence greater
numbers of metabolites. However, a wide range of column chemistries have been employed, as well
as a wide range of mobile phase solvent preparations, resulting in different retention times and adduct
formations, decreasing confidence in spectral matching with commercially and publicly available
spectral libraries.
3.4. Mass Spectrometry
3.4.1. Ionisation
For GC-MS platforms, ionisation is achieved most commonly by electron ionisation (EI) using
70 eV, however chemical ionisation using reagent gases such as methane and ammonia may be used.
EI is a hard ionisation technique causing considerable fragmentation of compounds. EI fragmentation
rarely allows detection of intact molecular masses, however the fragmentation patterns are highly
reproducible, allowing confident identification of features. Compounds with similar structures show
similar fragmentation patterns and are more difficult to identify without specialised chromatographic
methods preceding MS detection. Electrospray ionisation is most commonly used in LC-MS
applications and is a ‘soft’ ionisation technique, allowing the detection of intact compounds and
measurement of pseudo-molecular masses. ESI is less reproducible and depends heavily on the
specific mass analyser and manufacturer [65].
3.4.2. Mass Analysers
The most commonly employed mass analysers in metabolomics are quadrupole (Q), time-of-flight
(TOF) and ion trap (IT)/orbitrap, with tandem variations including triple quadrupole (QQQ), QTOF,
TOF/TOF, IT/TOF. Single and triple quadrupole systems generally provide unit mass resolution and,
in the case of the QQQ, high sensitivity. Time-of-flight instruments provide high resolution, accurate
mass data, as does the orbitrap. Kind et al. [88] have recently outlined common MS platforms and
their performance characteristics.
3.5. Data Processing and Analysis
Chromatography-mass spectrometry metabolomic data requires feature (mass-to-charge peak)
detection, deconvolution and retention time alignment. There are many software packages and
computational tools for this, both commercial and public, with one of the most commonly reported
peak picking and retention time alignment tools being XCMS [89] for LC-MS workflows. Deconvolution
is essentially the grouping of m/z ions of a single component and is essential for GC-EI-MS data [90].
Similar approaches are needed for LC-MS data where multiple adducts are present. We previously
mentioned quality control measures including pooled samples, reference samples and test mixtures.
At this point these should be utilised to determine the quality of data and remove features/samples
which are irreproducible including those which appear to be, for example, sample mismatches
or extreme values. Various forms of quality control measures for metabolomics studies have
recently been reviewed [91]. Statistical analyses are then conducted to prioritise identification and
interpretation of features from untargeted metabolomics experiments. Prior to statistical analyses,
centring, scaling or transformation of the data are carried out [92]. Tools such as PhenoMeNal [93],
Metabolomics Workbench [94] and MetaboAnalyst [95–100] offer data analysis solutions.
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3.6. Metabolite Identification and Interpretation of Findings
3.6.1. Identification
For targeted experiments, metabolite identification is considered in the early stages of the
chosen data analysis pipeline, but for untargeted approaches, it is usually the final stage of data
processing, occurring after metabolites of interest have been determined. For targeted experiments,
authentic reference standards are purchased and analysed ahead of the experiment. In untargeted
experiments, commercial and public spectral libraries are used, as well as online databases to match
and putatively identify MS, as well as MS/MS and MSn experimental spectra [88]. These identifications
may be supported by purchasing the authentic reference standard, or laboratories may have in-house
platform-specific spectral libraries for confirmation of metabolite identifications.
Reporting the confidence of metabolite identifications in metabolomic experiments has recently
been addressed in the literature [101,102]. Initially, levels of identification were proposed [80] where,
as described by Sumner et al. [80], a Level 1 identification is confirmed with an authentic standard
of the compound and Level 4 is an unidentified compound. Schymanski et al. [103] described five
identification levels for high resolution data where, similar to Sumner et al., [80], Level 1 is confirmed
with an authentic standard. Level 4 is unidentified, but has an unequivocal molecular formula and
Level 5 is a ‘mass of interest’. More recently, Sumner et al. [102] proposed alphanumeric scoring
metrics for metabolite identification in order to communicate the confidence in an identification.
3.6.2. Interpretation
The biological interpretation of data relies first on the identification of significant metabolites
and second on mapping those metabolites to biochemical pathways and validating these data with
other sources of data such as, for example, HMDB [60–63], GWAS Catalog [104], SNiPA [105],
PhenoScanner [106] and www.metabolomix.com. Examples of currently available resources
for mapping metabolites to biochemical pathways include the BioCyc database collection [107],
KEGG pathway database [108], MetaboAnalyst [95–100,109], the Small Molecule Pathway Database
(SMPDb; [110,111]) and Recon3D [112].
4. Findings from Metabolomic Studies of Kidney Disease
Metabolomics in the study of kidney disease has been reviewed over the past five
years [8,12,113–119], elegantly summarising the application of metabolomics to kidney disease and the
recent findings of such studies. A selection of recent metabolomic studies of kidney disease has been
included here (Table 2), providing the disease, model, lowest recorded n per sample group, sample type
and platform on which the metabolomic data was acquired. Metabolomic-based kidney disease studies
have been carried out using mouse and rat models, but the majority of studies listed here have used
human participants. Many of the studies presented in Table 2 reported relatively low sample numbers.
For studies using animal models where experimental conditions are highly controlled, this may be less
of an issue. For studies using human participants, however, especially for CKD where the cause of
kidney disease may be variable, this issue has started to be addressed with eight studies since 2015
reporting >50 subjects per group. Indeed, two of these studies reported sample numbers approaching
1000 per group. Whether urine, plasma, serum or kidney tissue were used, many of the same markers
have been found. For example, hippuric and uric acids have been shown to discriminate kidney
disease based on urine [120], serum [121] and kidney tissue [122]. Moreover, uric acid has been
detected using both GC- [120] and LC-MS [121]. Hippuric and uric acids have been found as markers
for both CKD [121] and PKD [120].
We have included a range of sample numbers, types, and analytical platforms to begin to assess
overlapping biochemical processes. Table 3 shows metabolites which have been reported as important
for two or more of the seven kidney diseases listed in Table 2. Although this list is only a snapshot of
the currently available literature, it provides biochemical insight into some of the common processes
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linking kidney diseases. With allantoin and quinolinic acid each found in four of seven kidney diseases
we propose that purine metabolism and tryptophan metabolism via the kynurenine pathway are
important for kidney diseases.
4.1. Purine Metabolism
Allantoin is a product of purine metabolism excreted in the urine of most mammals except
in humans, where uric acid is usually excreted [63], unless it is first oxidised to allantoin [155].
Allantoin was reported in studies of CKD, diabetic nephropathy, PKD and kidney transplantation
(Table 3) and uric acid in CKD, diabetic nephropathy and PKD. Xanthosine and hypoxanthine were
reported in CKD and transplantation, and CKD and PKD respectively, further supporting the role
of purine metabolism in kidney disease. In humans, allantoin has been proposed as a marker of
oxidative stress [155], however in this collection of studies, allantoin was only found in rat models
of disease [120,122,129,139,147,152]. Two studies of CKD using human participants reported uric
acid [121,126], the synthesis of which has been directly linked to oxidative stress [156] through the
conversion of xanthine dehydrogenase to xanthine oxidase, a known source of reactive species [156].
Uric acid as a uremic toxin/retention solute may also be a source of oxidative stress [156].
4.2. Tryptophan Metabolism
Quinolinic acid is synthesized from tryptophan via the kynurenine pathway [157]. This metabolite,
reported for CKD, transplant, membranous nephropathy and kidney cancer, as well as the metabolites
kynurenic acid, tryptophan and indoleacetic acid, suggests that tryptophan metabolism plays a role in
kidney diseases. The kynurenine pathway has previously been associated with oxidative stress and
inflammation in ESRD patients [158]. Furthermore, it has been demonstrated that the ratio between
plasma kynurenic acid and tryptophan is a robust indicator of kidney function [159] and that there may
be involvement of the tryptophan pathway in chronic kidney disease possibly via increased activity of
the enzymes kynurenine aminotransferase (KAT), indoleamine 2,3-dioxygenase (IDO) in the kidney
and/or tryptophan 2,3-dioxygenase (TDO) in the liver.
5. Conclusions
Metabolomics studies have provided many candidate small molecules which may be appropriate
as biomarkers for kidney disease and also for elucidating mechanisms in disease onset and progression.
Here we have determined that both purine metabolism and tryptophan metabolism are likely
to play key roles in kidney disease since allantoin and quinolinic acid have been consistently
reported, as have other metabolites of their respective biochemical pathways. These metabolites
and pathways have previously been linked with oxidative stress and inflammation which are known
complications of kidney disease and may contribute to the progression of chronic kidney disease to
ESRD. These interpretations are limited however to the mapping of identified metabolites to pathways,
while many important features remain unidentified. As databases grow, these data can be further
interrogated to understand kidney diseases.
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